Home/MediciNova/Kazuko Matsuda

KM

Kazuko Matsuda

Chief Medical Officer

Therapeutic Areas

Neurology Respiratory Fibrotic Diseases

MediciNova Pipeline

Drug	Indication	Phase
MN-166 (ibudilast)	Progressive Multiple Sclerosis	Phase 3
MN-221 (bedoradrine)	Acute Exacerbations of Asthma	Phase 3
MN-001 (tipelukast)	Liver Fibrosis (NASH)	Phase 2

Leadership Team at MediciNova

President, Chief Executive Officer, and Founder

Chief Business Officer

Jason J. Kruger

Chief Financial Officer

View full MediciNova profile